Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

PHASE2TerminatedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 27, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

April 3, 2024

Conditions
Generalized Myasthenia GravisMyasthenia Gravis
Interventions
DRUG

ALXN2050

Oral tablet.

DRUG

Placebo

Oral tablet.

Trial Locations (46)

10117

Research Site, Berlin

11000

Research Site, Belgrade

11042

Research Site, New Hyde Park

11101

Research Site, Taipei

18000

Research Site, Niš

19104

Research Site, Philadelphia

20133

Research Site, Milan

20246

Research Site, Hamburg

24127

Research Site, Bergamo

27514

Research Site, Chapel Hill

28046

Research Site, Madrid

28207

Research Site, Charlotte

29010

Research Site, Málaga

30120

Research Site, Murcia

33100

Research Site, Udine

33487

Research Site, Boca Raton

33612

Research Site, Tampa

33952

Research Site, Port Charlotte

37232

Research Site, Nashville

40225

Research Site, Düsseldorf

40508

Research Site, Lexington

41009

Research Site, Seville

41404

Research Site, Daegu

44791

Research Site, Bochum

45069

Research Site, West Chester

50612

Research Site, Yangsan

53228

Research Site, Milwaukee

56100

Research Site, Pisa

77030

Research Site, Houston

78229

Research Site, San Antonio

80045

Research Site, Aurora

80131

Research Site, Napoli

85028

Research Site, Phoenix

97002

Research Site, Hualien City

97239

Research Site, Portland

97477

Research Site, Springfield

T6G 2R7

Research Site, Edmonton

N6A 4L6

Research Site, London

M5G 2C4

Research Site, Toronto

04103

Research Site, Leipzig

00168

Research Site, Roma

00189

Research Site, Rome

03080

Research Site, Seoul

06351

Research Site, Seoul

08036

Research Site, Barcelona

Unknown

Research Site, Taoyuan

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY